fashion -WSS

fashion

author：explore 2025-09-30 01:12:15 - browse：4338

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Lecanemab for Alzheimer's is coming. Is the health system ready?

WSS

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Should insurance cover cosmetic surgery?

Stroke rates rising, especially in working

Study: Pain burden is higher in Black NFL players than white ones

Bulgari apologizes to China for listing Taiwan as a country after online backlash

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Wikipedia

fashion

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Hospitals need to get ahead of regulations on climate change

Affirmative action in medical school literally saved lives

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Jerome Adams on the need for new antivirals for Covid

Leqembi, other new Alzheimer’s drugs require better biomarkers

The cancer drug shortage isn’t new — and neither are the solutions

Why some fertility treatments produce more boy babies

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Decentralized clinical trials need collaboration to achieve wider use

explore

How the political right came to back psychedelics to treat trauma

A new study sees potential in DNA sequencing of infants

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Charles Manson follower Leslie Van Houten released from prison after 53 years

Why ADHD is under

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

knowledge

knowledge

focus

explore